↓ Skip to main content

Immunophenotypic transformation in relapsed/refractory mantle cell lymphoma treated with human anti-CD5 chimeric antigen receptor T cells: A Case Report

Overview of attention for article published in Frontiers in Hematology, November 2022
Altmetric Badge

Mentioned by

reddit
1 Redditor

Citations

dimensions_citation
1 Dimensions

Readers on

mendeley
1 Mendeley
You are seeing a free-to-access but limited selection of the activity Altmetric has collected about this research output. Click here to find out more.
Title
Immunophenotypic transformation in relapsed/refractory mantle cell lymphoma treated with human anti-CD5 chimeric antigen receptor T cells: A Case Report
Published in
Frontiers in Hematology, November 2022
DOI 10.3389/frhem.2022.967156
Authors

Sha He, Xia Mao, Zhaoting Cheng, Xiaojian Zhu, Min Xiao, Jianfeng Zhou

Attention Score in Context

Attention Score in Context

This research output has an Altmetric Attention Score of 1. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 29 December 2023.
All research outputs
#23,324,704
of 25,992,468 outputs
Outputs from Frontiers in Hematology
#1
of 1 outputs
Outputs of similar age
#371,474
of 435,134 outputs
Outputs of similar age from Frontiers in Hematology
#1
of 1 outputs
Altmetric has tracked 25,992,468 research outputs across all sources so far. This one is in the 1st percentile – i.e., 1% of other outputs scored the same or lower than it.
So far Altmetric has tracked 1 research outputs from this source. They receive a mean Attention Score of 0.2. This one scored the same or higher as 0 of them.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 435,134 tracked outputs that were published within six weeks on either side of this one in any source. This one is in the 1st percentile – i.e., 1% of its contemporaries scored the same or lower than it.
We're also able to compare this research output to 1 others from the same source and published within six weeks on either side of this one. This one has scored higher than all of them